Our previous study demonstrated that lenvatinib synergizes with EGFR inhibitors mainly by abrogating the MAPK signaling mediated by FGFRs and EGFR, respectively, which may explain the main reasons for the failure of the above phase III SEARCH trial.11,26 Subsequently, a number of related studies confirmed that combination of EGFR and FGFRs inhibition can achieve promising antitumor effect in various cancer types, such as FGFR-driven urothelial cancer,27 FGFR2 fusion-positive cholangiocarcinoma,28 and non-small cell lung cancer (NSCLC).29 Here, FGFR2 is linked to non-small cell lung carcinoma.